CANbridge in $591 Million Deal with LogicBio for Gene Therapies

CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus (AAV) sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge also will have an option on sL65 for two additional indications and an option on LogicBio's lead drug, LB-001, in China . CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. If the other two options are exercised and all milestones are achieved, CANbridge would make $581 million in payments. Based in Boston , LogicBio develops gene therapies for rare diseases in children. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.